Publication:
Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir

0
0

Issued Date

2008

Resource Type

Letter

File Type

application/pdf

ISSN

15254135

DOI

10.1097/QAI.0b013e318157b0da

Other identifier(s)

2-s2.0-39049117418

Rights Holder(s)

Scopus

Bibliographic Citation

Journal of Acquired Immune Deficiency Syndromes. Vol 47, No.1 (2008), p.127-129

Suggested Citation

Manosuthi W., Sungkanuparph S., Ruxrungtham K., Prasithsirikul W., Athichathanabadi C., Tantisiriwat W., Bowonwatanuwong C., Chumpathat N., Chaovavanich A. Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir. Journal of Acquired Immune Deficiency Syndromes. Vol 47, No.1 (2008), p.127-129. doi:10.1097/QAI.0b013e318157b0da Retrieved from: https://hdl.handle.net/20.500.14740/4190

Title

Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir

Author(s)

Manosuthi W.
 Sungkanuparph S.
 Ruxrungtham K.
 Prasithsirikul W.
 Athichathanabadi C.
 Tantisiriwat W.
 Bowonwatanuwong C.
 Chumpathat N.
 Chaovavanich A.

Abstract

[No abstract available]

Subject(s)

Atazanavir
 Proteinase inhibitor
 Ritonavir
 RNA directed DNA polymerase inhibitor
 Saquinavir
 Virus RNA
 Atazanavir
 Oligopeptide
 Proteinase inhibitor
 Pyridine derivative
 Ritonavir
 Saquinavir
 Adult
 Aminotransferase blood level
 Blood sampling
 CD4 lymphocyte count
 Clinical article
 Controlled study
 DNA polymorphism
 Drug blood level
 Drug efficacy
 Drug safety
 Drug tolerability
 Dyslipidemia
 Female
 High performance liquid chromatography
 Human
 Human immunodeficiency virus infection
 Hyperbilirubinemia
 Letter
 Low drug dose
 Male
 Practice guideline
 Priority journal
 Salvage therapy
 Side effect
 Steady state
 Treatment duration
 Treatment outcome
 Virus resistance
 Article
 Drug administration
 Drug combination
 Drug Administration Schedule
 Drug Therapy, Combination
 HIV Infections
 HIV Protease Inhibitors
 Humans
 Oligopeptides
 Pyridines
 Ritonavir
 Saquinavir

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/4190

Collections

Scopus: Year 1983-2021

Endorsement

Review

Supplemented By

Referenced By